FRANKFURT (dpa-AFX) - Gerresheimer shares slipped further on Thursday after the conference call on quarterly figures and business outlook.

Recently, as the second weakest stock in the somewhat lower MDax, they tested the 50-day line, which is regarded as an indicator for the medium-term trend, with a drop of 4.2 percent to 101.60 euros. The 200-day line for the longer-term trend is also in danger, currently at just over EUR 100. On balance, the share price has made little progress in recent weeks since the end of February.

The specialty packaging manufacturer, which focuses on the pharmaceutical industry, is likely to continue to feel the effects of customer destocking in the second quarter. However, the management is hoping for an improvement from the summer. Gerresheimer confirmed its outlook for 2024 and also 2025. Analyst Sven Kürten from DZ Bank saw no surprise in this.

Nevertheless, some investors may have wished for more clarity regarding the end of the destocking. In an interview with the financial news agency dpa-AFX this morning, CFO Bernd Metzner had already explained that the reduction was slowing down but would still be felt in the second quarter. By the end of the quarter, however, the worst will probably be over.

For the 2024 financial year, Schott Pharma's competitor is still aiming for a 5 to 10 percent increase in sales from its own resources. According to CFO Metzner, the targets could be narrowed down and specified when the figures for the second quarter of the year are published in July. Then there will be more clarity overall./ajx/mis